Paraganglioma
MONDO:0000448A benign or malignant neoplasm arising from paraganglia located along the sympathetic or parasympathetic nerves. Infrequently, it may arise outside the usual distribution of the sympathetic and parasympathetic paraganglia. Tumors arising from the adrenal gland medulla are called pheochromocytomas. Morphologically, paragangliomas usually display a nesting (Zellballen) growth pattern. There are no reliable morphologic criteria to distinguish between benign and malignant paragangliomas. The only definitive indicator of malignancy is the presence of regional or distant metastases.
Also known as: Paraganglionic neoplasm, Paraganglionic tumor, Paraganglionic tumour, neoplasm of paraganglion, neoplasm of the paraganglion, paraganglioma, paragangliomas, paraganglion neoplasm
1516 clinical trials for this condition and its sub-types, 53 tagged with Paraganglioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Paraganglioma
-
Sympathetic paraganglioma 0 trials · 16 incl. sub-types
2 sub-types
- Adrenal gland pheochromocytoma 5 trials · 16 incl. sub-types Sub-types →
- Extra-adrenal sympathetic paraganglioma 0 trials
-
Head and neck paraganglioma 1 trial
4 sub-types
- Carotid body paraganglioma 0 trials Sub-types →
- Jugulotympanic paraganglioma 0 trials Sub-types →
- Tympanic paraganglioma 0 trials
- Vagus nerve paraganglioma 0 trials
-
Non-secreting paraganglioma 0 trials
1 sub-type
- Non-secreting chemodectoma 0 trials
-
Parasympathetic paraganglioma 0 trials
4 sub-types
- Carotid body paraganglioma 0 trials Sub-types →
- Jugulotympanic paraganglioma 0 trials Sub-types →
- Neoplasm of aortic body 0 trials
- Vagus nerve paraganglioma 0 trials
-
3 sub-types
- Multiple paragangliomas associated with polycythemia 0 trials
- Sporadic pheochromocytoma 0 trials
- Sporadic secreting paraganglioma 0 trials
Most studied deeper sub-types
-
Experimental kidney cancer drug trial halted early
Disease control Stopped earlyThis early-stage trial tested a new drug called DFF332, which targets a protein (HIF2α) that helps some cancers grow. The study included 40 adults with advanced clear cell renal cell carcinoma or other cancers with specific gene changes. DFF332 was tested alone and in combination…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental cancer drug tested in rare tumors, but trial stopped early
Disease control Stopped earlyThis phase 2 trial tested the drug guadecitabine (SGI-110) in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, and HLRCC-related kidney cancer that had not responded to other treatments. Participants received daily injections for 5 …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental vaccine combo for rare adrenal cancers shows early promise but trial halted
Disease control Stopped earlyThis early-phase trial tested a new therapeutic vaccine (EO2401) combined with the immunotherapy drug nivolumab in 70 people with advanced adrenocortical carcinoma or malignant pheochromocytoma/paraganglioma. The goal was to see if the combination is safe and can shrink tumors or…
Phase 1/2 • Sponsor: Enterome • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC